ArticleCureus2025
Integrating Prostate-Specific Antigen Density With Magnetic Resonance Imaging (MRI) Likert Scoring to Minimize Overdiagnosis: A Retrospective Cohort Study at Blackpool Teaching Hospitals.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Overdiagnosis and unnecessary prostate biopsies remain significant challenges in prostate cancer screening. This study addresses the limited integration of prostate-specific antigen density (PSAD) with magnetic resonance imaging (MRI) Likert scoring in large retrospective UK cohorts. We hypothesized that combining PSAD thresholds with MRI Likert scores would improve diagnostic specificity and reduce unnecessary biopsies compared to MRI assessment alone. Methodology We conducted a retrospective cohort study of 958 men who underwent transperineal prostate biopsy between 2019 and 2023 at a single tertiary center. Serum PSA and MRI-derived prostate volumes were used to calculate PSAD, with volumes obtained on T2-weighted MRI using an ellipsoid formula. Measurements were performed on institutional reporting software by two independent radiologists to assess interobserver consistency. PSAD thresholds of 0.10, 0.15, and 0.25 ng/mL/cc were evaluated. Clinically significant prostate cancer (csPCa) was defined as a Gleason Grade Group (GG) ≥ 3. Diagnostic accuracy metrics with 95% confidence intervals were calculated, and receiver operating characteristic (ROC) analysis was performed. Results The median age of the cohort was 69 years. Median PSAD rose progressively with increasing Gleason Grade Group (GG0: 0.10; GG1: 0.10; GG2: 0.153; GG3: 0.257; GG4: 0.35; GG5: 0.37 ng/mL/cc). A PSAD < 0.10 ng/mL/cc yielded a negative predictive value of 0.846 for csPCa, while a PSAD > 0.25 ng/mL/cc produced a positive predictive value of 0.624. The area under the ROC curve (AUC) for PSAD in predicting csPCa was 0.712, indicating fair discriminative ability. Conclusions PSAD serves as a cost-effective adjunct to MRI, enhancing risk stratification for csPCa. Integrating PSAD thresholds with MRI Likert scoring supports more precise biopsy decision-making and may reduce unnecessary procedures. These findings are supported by retrospective data and warrant prospective, multicenter validation to inform standardized clinical pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.